Ascelia Pharma’s Food Effect Study shows that Orviglance image enhancement of the liver is not reduced by light meal
Oncoral featured in the journal International Pharmaceutical Industry
In the April edition of the International Pharmaceutical Industry Journal, you can read about the science and our work to improve the outcomes for gastric cancer patients through our innovative daily oral chemotherapy drug candidate, Oncoral.
New market research shows strong support for Orviglance
Ascelia Pharma successfully completes Orviglance Hepatic Impairment Study
Ascelia Pharma today announced that the last patient visit has been completed in the clinical study to evaluate the effect of liver impairment on the safety, pharmacokinetics and pharmacodynamics of the company’s lead drug candidate Orviglance®.
Orviglance featured in the journal International Clinical Trials
In the February 2022 edition of the journal International Clinical Trials, you can read about our novel contrast agent Orviglance.